Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

AML (Acute Myeloid Leukemia): full-pipeline trial registry

2 of 2 indexed AML (Acute Myeloid Leukemia) trials are currently recruiting.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

AML (Acute Myeloid Leukemia): 2 US clinical trials tracked, 2 recruiting.

AML (Acute Myeloid Leukemia) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Crossbow Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition aml-acute-myeloid-leukemia

OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

AML (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near AML (Acute Myeloid Leukemia)

AML (Acute Myeloid Leukemia) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for AML (Acute Myeloid Leukemia) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. AML (Acute Myeloid Leukemia) is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 4 1

Top Sponsors

Named interventions

Most-linked intervention names on AML (Acute Myeloid Leukemia) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CBX-250 Drug
1 trials
CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates Drug
1 trials
Olutasidenib Drug
1 trials

US sites by state

Facility locations filed on AML (Acute Myeloid Leukemia) trials. A trial with sites in several states counts in each.

New York 2 trials
California 2 trials
Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Missouri 1 trials
Massachusetts 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this AML (Acute Myeloid Leukemia) page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 AML (Acute Myeloid Leukemia) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Crossbow Therapeutics sponsors the most AML (Acute Myeloid Leukemia) trials on record, review their full trial history before evaluating a specific study. See Crossbow Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This AML (Acute Myeloid Leukemia) condition card totals 2 registered trials; most-linked intervention CBX-250; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.